20170406 Telix Logo.png
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
April 30, 2020 20:14 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
20170406 Telix Logo.png
Telix Pharmaceuticals and PI Medical Sign Distribution Agreement for the Netherlands
July 01, 2019 20:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and RAAMSDONKSVEER, Netherlands, July 02, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company...
Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership
January 23, 2019 19:15 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIEGE, Belgium, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Advanced Nuclear Medicine Ingredients SA (“ANMI”), a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX:TLX,...
Telix Group Expands Prostate Imaging Capability through ININ Technology Partnership
January 23, 2019 19:15 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIEGE, Belgium, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Advanced Nuclear Medicine Ingredients SA (“ANMI”), a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX:TLX,...